ReproCELL Inc (4978):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ReproCELL Inc (4978) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8092
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ReproCELL Inc (ReproCELL) is a biotechnology company that develops and commercializes stem cell technologies. The company offers products in divisions such as research reagents, cultivation materials, and cell and biorepository. Its research reagent products include hES iPSC culture reagents, human HSC culture reagent, reprogramming regent for iPSC, small molecule, pluripotency marker, and culture reagents for cancer research. ReproCELL’s cell and biorepository products comprise human iPS cells derived cardiomyocytes, hiPSC-neurons, hiPSC-hepatocytes, hiPSC-disease model cells and biorepository. The company markets its products across Japan. ReproCELL is headquartered in Yokohama, Japan.

ReproCELL Inc (4978) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReproCELL Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReproCELL Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 13
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 14
Venture Financing 15
Kringle Pharma Raises USD5.4 Million in Venture Financing 15
Reinnervate Secures USD0.16 Million in Venture Funding 17
Reinnervate Secures USD1.72 Million in Venture Funding 18
Stemgent Raises US$11.3 Million In Venture Financing 19
Stemgent Raises US$6.3 Million In Series C Financing 20
Partnerships 21
Q Therapeutics Forms Joint Venture with REPROCELL 21
Q Therapeutics Announces Research Agreement with ReproCELL 22
ReproCELL and Fox Chase Cancer Center Enter into Partnership 23
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Three-Dimensional Bioprinting Product Lines 24
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Cell Culture Products 25
ReproCELL Enters Into Distribution Agreement With Laboratorios Conda 26
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 27
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 28
Reinnervate Enters Into Co-Development Agreement With Kirkstall 29
Licensing Agreements 30
ReproCELL Receives Rights of Stemchymal Cell Therapy Technology from Steminent Biotherapeutics 30
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 31
Equity Offering 32
ReproCELL Completes IPO For US$20.8 Million 32
Asset Transactions 34
ReproCELL to Sell ReproHP Medium 34
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 35
Acquisition 36
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
ReproCELL Plans to Acquire 7.44% Stake in ReproCELL USA 37
ReproCELL to Acquire Biopta for USD8.2 Million 38
ReproCELL Acquires BioServe Biotechnologies 40
ReproCELL Acquires Reinnervate 41
ReproCELL Inc – Key Competitors 42
ReproCELL Inc – Key Employees 43
ReproCELL Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 45
Recent Developments 46
Other Significant Developments 46
Jun 21, 2018: Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
ReproCELL Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReproCELL Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReproCELL Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 13
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 14
Kringle Pharma Raises USD5.4 Million in Venture Financing 15
Reinnervate Secures USD0.16 Million in Venture Funding 17
Reinnervate Secures USD1.72 Million in Venture Funding 18
Stemgent Raises US$11.3 Million In Venture Financing 19
Stemgent Raises US$6.3 Million In Series C Financing 20
Q Therapeutics Forms Joint Venture with REPROCELL 21
Q Therapeutics Announces Research Agreement with ReproCELL 22
ReproCELL and Fox Chase Cancer Center Enter into Partnership 23
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Three-Dimensional Bioprinting Product Lines 24
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Cell Culture Products 25
ReproCELL Enters Into Distribution Agreement With Laboratorios Conda 26
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 27
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 28
Reinnervate Enters Into Co-Development Agreement With Kirkstall 29
ReproCELL Receives Rights of Stemchymal Cell Therapy Technology from Steminent Biotherapeutics 30
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 31
ReproCELL Completes IPO For US$20.8 Million 32
ReproCELL to Sell ReproHP Medium 34
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 35
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
ReproCELL Plans to Acquire 7.44% Stake in ReproCELL USA 37
ReproCELL to Acquire Biopta for USD8.2 Million 38
ReproCELL Acquires BioServe Biotechnologies 40
ReproCELL Acquires Reinnervate 41
ReproCELL Inc, Key Competitors 42
ReproCELL Inc, Key Employees 43
ReproCELL Inc, Other Locations 44
ReproCELL Inc, Subsidiaries 44
ReproCELL Inc, Joint Venture 45

List of Figures
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ReproCELL Inc (4978):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Camping World Holdings Inc (CWH):企業の財務・戦略的SWOT分析
    Camping World Holdings Inc (CWH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Statkraft AS:企業の戦略・SWOT・財務分析
    Statkraft AS - Strategy, SWOT and Corporate Finance Report Summary Statkraft AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • NeuroSearch AS (NEUR)-製薬・医療分野:企業M&A・提携分析
    Summary NeuroSearch A/S (NeuroSearch) focuses on the development of novel pharmaceutical agents for the treatment of various disorders of central nervous system (CNS) through license agreements with other life science companies. The company divested all rights of Huntexil for the treatment of patien …
  • Sevion Therapeutics Inc (SVON)-製薬・医療分野:企業M&A・提携分析
    Summary Sevion Therapeutics Inc (Sevion), formerly Senesco Technologies, Inc. is a pharmaceutical company that discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company has developed protein nanocage system that allows delivery of nucleic …
  • OptiNose US Inc (OPTN):製薬・医療:M&Aディール及び事業提携情報
    Summary OptiNose US Inc (OptiNose) is a specialty pharmaceutical company that develops and delivers new pipeline drugs through intranasal deposition of medications. The company offers products such as XHANCE fluticasone propionate and ONZETRA sumatriptan nasal powder. Its products are used in the th …
  • Invenergy LLC:企業の戦略的SWOT分析
    Invenergy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Airservices Australia:企業の戦略的SWOT分析
    Airservices Australia - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Thermo Fisher Scientific Inc.:企業の戦略・SWOT・財務情報
    Thermo Fisher Scientific Inc. - Strategy, SWOT and Corporate Finance Report Summary Thermo Fisher Scientific Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • City National Wealth Management:企業の戦略・SWOT・財務情報
    City National Wealth Management - Strategy, SWOT and Corporate Finance Report Summary City National Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • PT PLN (Persero):企業の発電所・SWOT分析2018
    PT PLN (Persero) - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Copper Mountain Mining Corporation:企業の戦略・SWOT・財務情報
    Copper Mountain Mining Corporation - Strategy, SWOT and Corporate Finance Report Summary Copper Mountain Mining Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Group Five Ltd:企業の戦略的SWOT分析
    Group Five Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Camlin Fine Sciences Limited:戦略・SWOT・企業財務分析
    Camlin Fine Sciences Limited - Strategy, SWOT and Corporate Finance Report Summary Camlin Fine Sciences Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Select Energy Services Inc (WTTR):企業の財務・戦略的SWOT分析
    Select Energy Services Inc (WTTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Mission Pharmacal Company:企業の戦略・SWOT・財務情報
    Mission Pharmacal Company - Strategy, SWOT and Corporate Finance Report Summary Mission Pharmacal Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Navy Exchange Service Command:企業の戦略・SWOT・財務情報
    Navy Exchange Service Command - Strategy, SWOT and Corporate Finance Report Summary Navy Exchange Service Command - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Afrimat Ltd:企業の戦略・SWOT・財務情報
    Afrimat Ltd - Strategy, SWOT and Corporate Finance Report Summary Afrimat Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Wegmans Food Markets, Inc.:企業の戦略・SWOT・財務分析
    Wegmans Food Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wegmans Food Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Interconexion Electrica SA ESP (ISA):企業の財務・戦略的SWOT分析
    Interconexion Electrica SA ESP (ISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Abiogen Pharma SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Abiogen Pharma SpA (Abiogen), a subsidiary of MDM Holding SpA, is a specialist pharmaceutical company, which develops, manufactures, and markets medicines with focus on musculo-skeletal health, and rare diseases. The company offers products in the form of oral solids, injectables, semi solid …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆